Chromatin Modifications Sequentially Enhance ErbB2 Expression in ErbB2-Positive Breast Cancers

Cell Reports

Volumn 5, Issue 2, 2013, Pages 302-313

  Mungamuri, SathishKumar ^a   Murk, William ^a   Grumolato, Luca ^a   Bernstein, Emily ^a   Aaronson, StuartA ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE LYSINE METHYLTRANSFERASE; TRASTUZUMAB; CHROMATIN; ERBB2 PROTEIN, HUMAN; HISTONE; HISTONE ACETYLTRANSFERASE PCAF; MONOCLONAL ANTIBODY; P300-CBP-ASSOCIATED FACTOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR AP 2; WDR5 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; GENE; GENE INTERACTION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; H3K4ME3 GENE; H3K9AC GENE; HISTONE MODIFICATION; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; WDR5 GENE; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL PROLIFERATION; CHEMISTRY; CHROMATIN; DRUG EFFECTS; FEMALE; GENETICS; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN; FEMALE; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; MCF-7 CELLS; P300-CBP TRANSCRIPTION FACTORS; RECEPTOR, ERBB-2; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR AP-2;

EID: 84887015315     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.09.009     Document Type: Article

References (59)

1. Andrechek E.R., Hardy W.R., Siegel P.M., Rudnicki M.A., Cardiff R.D., Muller W.J. Amplification of the neu/erbB-2 oncogene in a mousemodel of mammary tumorigenesis. Proc. Natl. Acad. Sci. USA 2000, 97:3444-3449.
2. Andrechek E.R., Laing M.A., Girgis-Gabardo A.A., Siegel P.M., Cardiff R.D., Muller W.J. Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers. Cancer Res. 2003, 63:4920-4926.
3. Ang Y.S., Tsai S.Y., Lee D.F., Monk J., Su J., Ratnakumar K., Ding J., Ge Y., Darr H., Chang B., et al. Wdr5 mediates self-renewal and reprogramming via the embryonic stem cell core transcriptional network. Cell 2011, 145:183-197.
4. Arrowsmith C.H., Bountra C., Fish P.V., Lee K., Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 2012, 11:384-400.
5. Bosher J.M., Williams T., Hurst H.C. The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. Proc. Natl. Acad. Sci. USA 1995, 92:744-747.
6. Bosher J.M., Totty N.F., Hsuan J.J., Williams T., Hurst H.C. A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene 1996, 13:1701-1707.
7. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., Rowland A.M., Kotts C., Carver M.E., Shepard H.M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 1992, 89:4285-4289.
8. Couture J.F., Collazo E., Trievel R.C. Molecular recognition ofhistone H3 by the WD40 protein WDR5. Nat. Struct. Mol. Biol. 2006, 13:698-703.
9. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., Kastritis E., Gilpatrick T., Paranal R.M., Qi J., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
10. Di Fiore P.P., Pierce J.H., Kraus M.H., Segatto O., King C.R., Aaronson S.A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987, 237:178-182.
11. Dou Y., Milne T.A., Tackett A.J., Smith E.R., Fukuda A., Wysocka J., Allis C.D., Chait B.T., Hess J.L., Roeder R.G. Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell 2005, 121:873-885.
12. Dou Y., Milne T.A., Ruthenburg A.J., Lee S., Lee J.W., Verdine G.L., Allis C.D., Roeder R.G. Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nat. Struct. Mol. Biol. 2006, 13:713-719.
13. Dougall W.C., Qian X., Peterson N.C., Miller M.J., Samanta A., Greene M.I. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 1994, 9:2109-2123.
14. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 2007, 8:286-298.
15. Esteller M. Epigenetics in cancer. N.Engl. J. Med. 2008, 358:1148-1159.
16. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
17. Fisher C.L., Fisher A.G. Chromatin states in pluripotent, differentiated, and reprogrammed cells. Curr. Opin. Genet. Dev. 2011, 21:140-146.
18. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., Jagiello-Gruszfeld A., Crown J., Chan A., Kaufman B., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N.Engl. J. Med. 2006, 355:2733-2743.
19. Grooteclaes M., Vernimmen D., Plaza S., Pasleau F., Hodzic D., Winkler-Gol R. A new cis element is involved in the HER2 gene overexpression in human breast cancer cells. Cancer Res. 1999, 59:2527-2531.
20. Guy C.T., Webster M.A., Schaller M., Parsons T.J., Cardiff R.D., Muller W.J. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 1992, 89:10578-10582.
21. Han Z., Guo L., Wang H., Shen Y., Deng X.W., Chai J. Structural basis for the specific recognition of methylated histone H3 lysine 4 by the WD-40 protein WDR5. Mol. Cell 2006, 22:137-144.
22. Hemshekhar M., Sebastin Santhosh M., Kemparaju K., Girish K.S. Emerging roles of anacardic acid and its derivatives: a pharmacological overview. Basic Clin. Pharmacol. Toxicol. 2011, 10.1111/j.1742-7843.2011.00833.
23. Kancha R.K., von Bubnoff N., Bartosch N., Peschel C., Engh R.A., Duyster J. Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib. PLoS ONE 2011, 6:e26760.
24. Kao J., Pollack J.R. RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. Genes Chromosomes Cancer 2006, 45:761-769.
25. Koutelou E., Hirsch C.L., Dent S.Y. Multiple faces of the SAGA complex. Curr. Opin. Cell Biol. 2010, 22:374-382.
26. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
27. Kraus M.H., Popescu N.C., Amsbaugh S.C., King C.R. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J. 1987, 6:605-610.
28. Mai A., Rotili D., Tarantino D., Ornaghi P., Tosi F., Vicidomini C., Sbardella G., Nebbioso A., Miceli M., Altucci L., Filetici P. Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties. J.Med. Chem. 2006, 49:6897-6907.
29. Muller W.J., Sinn E., Pattengale P.K., Wallace R., Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988, 54:105-115.
30. Mungamuri S.K., Yang X., Thor A.D., Somasundaram K. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res. 2006, 66:4715-4724.
31. Mungamuri S.K., Benson E.K., Wang S., Gu W., Lee S.W., Aaronson S.A. p53-mediated heterochromatin reorganization regulates its cell fate decisions. Nat. Struct. Mol. Biol. 2012, 19:478-484. S1.
32. Nadler Y., González A.M., Camp R.L., Rimm D.L., Kluger H.M., Kluger Y. Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer. Ann. Oncol. 2010, 21:466-473.
33. Nahta R., Esteva F.J. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006, 8:215.
34. Paik S., Kim C., Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N.Engl. J. Med. 2008, 358:1409-1411.
35. Patel A., Dharmarajan V., Vought V.E., Cosgrove M.S. On the mechanism of multiple lysine methylation by the human mixed lineage leukemia protein-1 (MLL1) core complex. J.Biol. Chem. 2009, 284:24242-24256.
36. Pegram M., Hsu S., Lewis G., Pietras R., Beryt M., Sliwkowski M., Coombs D., Baly D., Kabbinavar F., Slamon D. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999, 18:2241-2251.
37. Peltomäki P. Mutations and epimutations in the origin of cancer. Exp. Cell Res. 2012, 318:299-310.
38. Pero S.C., Daly R.J., Krag D.N. Grb7-based molecular therapeutics in cancer. Expert Rev. Mol. Med. 2003, 5:1-11.
39. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N.Engl. J. Med. 2005, 353:1659-1672. Herceptin Adjuvant (HERA) Trial Study Team.
40. Ramsey B., Bai T., Hanlon Newell A., Troxell M., Park B., Olson S., Keenan E., Luoh S.W. GRB7 protein over-expression and clinical outcome in breast cancer. Breast Cancer Res. Treat. 2011, 127:659-669.
41. Robert N., Leyland-Jones B., Asmar L., Belt R., Ilegbodu D., Loesch D., Raju R., Valentine E., Sayre R., Cobleigh M., et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J.Clin. Oncol. 2006, 24:2786-2792.
42. Rodríguez-Navarro S. Insights into SAGA function during gene expression. EMBO Rep. 2009, 10:843-850.
43. Rodríguez-Paredes M., Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 2011, 17:330-339.
44. Ruthenburg A.J., Wang W., Graybosch D.M., Li H., Allis C.D., Patel D.J., Verdine G.L. Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex. Nat. Struct. Mol. Biol. 2006, 13:704-712.
45. Santos-Rosa H., Schneider R., Bannister A.J., Sherriff J., Bernstein B.E., Emre N.C., Schreiber S.L., Mellor J., Kouzarides T. Active genes are tri-methylated at K4 of histone H3. Nature 2002, 419:407-411.
46. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
47. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
48. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N.Engl. J. Med. 2001, 344:783-792.
49. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., Mackey J., Glaspy J., Chan A., Pawlicki M., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N.Engl. J. Med. 2011, 365:1273-1283. Breast Cancer International Research Group.
50. Stein D., Wu J., Fuqua S.A., Roonprapunt C., Yajnik V., D'Eustachio P., Moskow J.J., Buchberg A.M., Osborne C.K., Margolis B. The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J. 1994, 13:1331-1340.
51. Steward M.M., Lee J.-S., O'Donovan A., Wyatt M., Bernstein B.E., Shilatifard A. Molecular regulation of H3K4 trimethylation by ASH2L, a shared subunit of MLL complexes. Nat. Struct. Mol. Biol. 2006, 13:852-854.
52. Thompson B.A., Tremblay V., Lin G., Bochar D.A. CHD8 is an ATP-dependent chromatin remodeling factor that regulates beta-catenin target genes. Mol. Cell. Biol. 2008, 28:3894-3904.
53. Trievel R.C., Shilatifard A. WDR5, a complexed protein. Nat. Struct. Mol. Biol. 2009, 16:678-680.
54. Vardabasso C., Hasson D., Ratnakumar K., Chung C.Y., Duarte L.F., Bernstein E. Histone variants: emerging players in cancer biology. Cell. Mol. Life Sci. 2013, Published online May 8, 2013. 10.1007/s00018-013-1343-z.
55. Wajapeyee N., Britto R., Ravishankar H.M., Somasundaram K. Apoptosis induction by activator protein 2alpha involves transcriptional repression of Bcl-2. J.Biol. Chem. 2006, 281:16207-16219.
56. Wysocka J., Swigut T., Milne T.A., Dou Y., Zhang X., Burlingame A.L., Roeder R.G., Brivanlou A.H., Allis C.D. WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development. Cell 2005, 121:859-872.
57. Xu W., Edmondson D.G., Evrard Y.A., Wakamiya M., Behringer R.R., Roth S.Y. Loss of Gcn5l2 leads to increased apoptosis andmesodermal defects during mouse development. Nat. Genet. 2000, 26:229-232.
58. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2:127-137.
59. Zuber J., Shi J., Wang E., Rappaport A.R., Herrmann H., Sison E.A., Magoon D., Qi J., Blatt K., Wunderlich M., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.